## PRELIMINARY SCIENTIFIC PROGRAMME

**Optimising Drug Therapy: An Imperative for World Health**

**Parallel Symposium**

The era of personalised health care: Impact on drug discovery and development?

**Sponsoring Organisation**

Co-chairs
- M. E. Brewster, Beere, Belgium
- W. Sadee, Columbus, OH USA
- Y. Sugiyama, Tokyo, Japan

**08:30**
- Evaluating molecular genetic factors in drug response: Search for targets and biomarkers
  - W. Sadee, Columbus, OH USA
- Predicting drug disposition and response in individual patients
  - Y. Sugiyama, Tokyo, Japan

**09:05**
- Is gene/protein delivery delivering?
  - H. Harashima, Sapporo, Japan
- Can ADME and PK be predicted from in silico/in vitro data?
  - Y. Sugiyama, Tokyo, Japan

**09:40**
- Coffee Break

**10:10**
- Biomarkers in drug development: How do they influence clinical practice?
  - L. J. Lesko, Bethesda, MD USA
- Non-viral delivery of genes and oligonucleotides
  - J. Huang, Chapel Hill, NC USA

**10:45**
- Short Podium Presentation
- Short Podium Presentation

**11:00**
- Short Podium Presentation

**11:15**
- Keynote Presentation
- Transforming ‘art’ into ‘science’ in dosage form design – achievements and challenges
  - P. York, Bradford, United Kingdom
- What are the main challenges for world health? What should be done now and in the future?
  - R. Laing, Geneva, Switzerland

**12:15**
- Round Table Discussion
- Science or business as the driver of new drug development?
  - Convenor L.Z. Benet, San Francisco, CA USA

**13:10**
- Pharmacogenetics at the bedside?
  - G.T. Tucker, Sheffield, United Kingdom
- What will be the impact of cell-based therapy?
  - E. Cattaneo, Milan, Italy

**14:15**
- Pharmacogenetics – how far is reality from expectation?
  - G.T. Tucker, Sheffield, United Kingdom
- Innovative neurogenic neural stem cell lines for neurodegenerative disease
  - E. Cattaneo, Milan, Italy

**15:25**
- Pharmacogenetics in cancer therapy
  - M. Relling, Memphis, TN USA
- Cardiac regeneration: Repopulating the heart
  - L. J. Field, Indianapolis, IN USA

**16:00**
- Short Podium Presentation
- Short Podium Presentation

**16:15**
- Short Podium Presentation
- Short Podium Presentation

**16:45**
- See framed information, page 11
PROGRAMME • Monday

Parallel Symposium
Metabolomics: What are the opportunities for biomarker discovery?

Co-chairs
T. Hankemeier, Leiden, The Netherlands
G. Harrigan, St Louis, MO USA

08:30
Systems biology and metabolomics: How far are we?
T. Hankemeier, Leiden, The Netherlands

Parallel Symposium
Metabolomics in Reverse Pharmacology
G. Harrigan, St Louis, MO USA

09:40
Coffee Break

Parallel Symposium
Metabolomics by CE-MS for biomarker discovery
T. Soga, Keio, Japan

10:10
Towards the desired state: a retrospective and prospective view on PAT
A. Hussein, Princeton, NJ USA

10:45
Short Podium Presentation

11:00
Short Podium Presentation

11:15
Lunch Break

Parallel Symposium
Dirty vs selective drugs in the CNS?

Sponsoring Organisation
Solvay Pharmaceuticals

Co-chairs
H. Meltzer, Nashville, TN USA
C. Kruse, Weesp, The Netherlands

13:10
Rational polypharmacy within a single molecule: The basis for current antipsychotic treatment
H. Meltzer, Nashville, TN USA

14:15
The treatment of major depression: Single or multiple targets?
F. Artilgas, Barcelona, Spain

15:25
Muscarnic receptors as a target in the treatment of disorders of the CNS: Antagonism, agonism or both?
B. Dean, Parkville, Australia

16:00
Short Podium Presentation

16:15
Short Podium Presentation

Parallel Symposium
How will developments in chemical methods sustain pharmaceutical industrial development?

Co-chairs
T. Ohwada, Tokyo, Japan

14:50
Process chemistry as leverage for drug development and profitability in the pharmaceutical industry
T. Konoike, Moelndal, Sweden

15:05
Folate conjugates of biologically active compounds – discovery and development
J. Vilahov, West Lafayette, IN USA

15:20
The synthetic development of the anti-influenza neuraminidase inhibitor oseltamivir phosphate (Tamiflu): A challenge for synthesis and process research
M. Karpf, Leiden, The Netherlands

15:35
Short Podium Presentation

15:50
Short Podium Presentation

Parallel Symposium
How effective is the globalisation/harmonisation of pharmacovigilance?

Endorsing Organisation
EUMAPP Project on microdosing

Co-chairs
F. Lekkerkerker, The Hague, The Netherlands
M. Braun, Rockville, MD USA

16:15
The science underlying the practice of pharmacovigilance
N. Moore, Bordeaux, France

16:30
International variety in interpretation and management of drug safety
N. Waishon, London, United Kingdom

16:45
ICH, CIOMS, ISOP, ISPE and other acronymic vehicles to enable harmonization of pharmacovigilance
C.-K. Shim, Seoul, Korea

17:00
Round Table Discussion

Proactive risk management (plans): where are we?
Convenor F. Lekkerkerker, The Hague, The Netherlands

This Symposium is a special one, organised on the occasion of the retirement of Dr F. Lekkerkerker, Chair of the Dutch Medicines Evaluation Board (MEB), which is supporting it. It will be followed by a Reception for guests invited by the MEB.
Parallel Symposium
Druggability: A concept that will fill the pipeline?

Co-chairs
D. Nicholson, Oss, The Netherlands

08:30
Druggability and the concept of ADME space
D. Smith, Sandwich, United Kingdom

Druggability: The broader and the physicochemical views
B. Testa, Lausanne, Switzerland

09:05
Concave druggability of protein surfaces for accelerating in silico screening
H. Shirai, Ibarakai, Japan

09:40
Coffee Break

10:10
Improved Targeting with Molecules Decorated Nanoparticles
N. Peppas, Austin, TX USA

10:45
Structure-based virtual screening
B. Shoicet, San Francisco, CA USA

11:00
Short Podium Presentation

11:15
Posters

12:15
Are we meeting the challenges of resistance to anti-infective drugs and of newly emerging infectious diseases?
L. Schlesinger, Columbus OH USA

13:10
Translational science: a solution to the productivity gap?
Convenor D. Nicholson, Oss, The Netherlands

14:15
Managing herb-drug interactions: Understanding mechanism and educating the public
A. McClellan, Sydney, Australia

14:50
Role of the pharmacist in avoiding drug-drug interactions with patient self-care
E. Nakashima, Tokyo, Japan

15:25
Application of a drug-drug interaction database in drug development and clinical education
K. Thummel, Seattle, WA USA

16:00
Short Podium Presentation

16:15
Eligibility as a criterion for the use of intravenous anaesthesia agents
A. Grahnen, Uppsala, Sweden

EUFEPS Afternoon Session

See framed information, page 11

See framed information, page 11

See framed information, page 11
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Parallel Symposium: What’s new in methods of measuring human drug response?</td>
</tr>
<tr>
<td></td>
<td>Co-chairs: A. Cohen, Leiden, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>P. Macheras, Athens, Greece</td>
</tr>
<tr>
<td>09:05</td>
<td>Pathophysiological concepts as a basis for the measurement of treatment response in inflammatory and obstructive airway disease</td>
</tr>
<tr>
<td></td>
<td>Co-chairs: A. Cohen, Leiden, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>H. Reddel, Sydney, Australia</td>
</tr>
<tr>
<td>08:30</td>
<td>Parallel Symposium: In silico product development from molecule to man: Dream or reality?</td>
</tr>
<tr>
<td></td>
<td>Co-chairs: P. York, Bradford, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>V. Venkatosubramanian, West Lafayette, IN USA</td>
</tr>
<tr>
<td>09:05</td>
<td>Thermodynamics of pharmaceutical systems from molecular simulation</td>
</tr>
<tr>
<td></td>
<td>J. Anwar, Bradford, United Kingdom</td>
</tr>
<tr>
<td>09:40</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:10</td>
<td>Parallel Symposium: Have omics technologies improved the chance for successful drug development?</td>
</tr>
<tr>
<td></td>
<td>Co-chairs: T. Guentert, Basel, Switzerland</td>
</tr>
<tr>
<td>10:45</td>
<td>Short Podium Presentation</td>
</tr>
<tr>
<td>11:00</td>
<td>Short Podium Presentation</td>
</tr>
<tr>
<td>11:15</td>
<td>Posters Lunch Break</td>
</tr>
<tr>
<td>12:15</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>13:10</td>
<td>Parallel Symposium: Genomics and drug discovery: Have the promises been fulfilled?</td>
</tr>
<tr>
<td></td>
<td>Co-chairs: K. Lindpaintner, Basel, Switzerland</td>
</tr>
<tr>
<td></td>
<td>R. Bleavins, Ann Arbor, MI USA</td>
</tr>
<tr>
<td>14:15</td>
<td>Short Podium Presentation</td>
</tr>
<tr>
<td>14:50</td>
<td>Short Podium Presentation</td>
</tr>
<tr>
<td>15:25</td>
<td>Short Podium Presentation</td>
</tr>
<tr>
<td>16:00</td>
<td>Short Podium Presentation</td>
</tr>
<tr>
<td>16:15</td>
<td>Short Podium Presentation</td>
</tr>
</tbody>
</table>
## PRELIMINARY SCIENTIFIC PROGRAM

### Parallel Symposium
**How to manage drug therapy at the extremes of age?**

Co-chairs
- H. Derendorf, Gainesville, FL USA
- H. Christensen, Oslo, Norway

*08:30*
- Pharmacotherapy in the elderly
  - H. Derendorf, Gainesville, FL USA

*09:05*
- Pharmacokinetics and pharmacodynamics in neonates and infants
  - T. Dalla Costa, Porto Alegre, Brazil

*09:40*
- Coffee Break

*10:10*
- Dose optimisation in children
  - S. Higuchi, Fukuoka, Japan

*10:45*
- Short Podium Presentation
  - S. Higuchi, Fukuoka, Japan

*11:00*
- Short Podium Presentation
  - S. Higuchi, Fukuoka, Japan

*11:15*
- Posters
  - Lunch Break

**Keynote Presentation**

*12:15*
- Drug resistance in cancer chemotherapy
  - T. Tsuruo, Tokyo, Japan

*13:10*
- What is the value of observational data post-marketing to assess safety and efficacy?
  - Convenor M. Rowland, Manchester, United Kingdom

**Parallel Symposium**
**Developing biotech products: What are the challenges and solutions?**

Co-chairs
- M. Roberts, Brisbane, Australia
- J. Kennedy, Cork, Ireland

*14:15*
- When are dose administration aids of benefit?
  - M. Roberts, Brisbane, Australia

*14:50*
- Clinical and economic impact of patient’s variable adherence
  - J. Unguhart, San Francisco, CA USA, and Maastricht, The Netherlands

*15:25*
- Medication errors and human factors in medication use safety
  - P. Schneider, Columbus, OH USA

*16:00*
- Short Podium Presentation
  - Short Podium Presentation

*16:15*
- Short Podium Presentation
  - Short Podium Presentation

**EUFEPS Afternoon Session**

*16:45*
- See framed information, page 11

---

**Parallel Symposium**
**How can nanotechnology and materials science solve drug delivery problems?**

Co-chairs
- C-M. Lehr, Saarbrucken, Germany

*09:05*
- Nanotechnology for overcoming biological barriers
  - C. M. Lehr, Saarbrucken, Germany

*09:40*
- Coffee Break

*10:10*
- Can higher definition of the nanoscale result in better drug delivery systems in the 21st century?
  - H. Ghandehari, Baltimore, USA

*10:45*
- Short Podium Presentation
  - H. Ghandehari, Baltimore, USA

*11:00*
- Short Podium Presentation
  - H. Ghandehari, Baltimore, USA

*11:15*
- Posters
  - Lunch Break

**Keynote Presentation**

*12:15*
- Will an understanding of the molecular genetic basis of neurodegenerative disease lead to effective treatments?
  - A. Aguzzi, Zurich, Switzerland

*13:10*
- Life-style drugs: a new burden to the health system?
  - Convenor G. Alvan, Uppsala, Sweden

**Parallel Symposium**
**Control of intracellular pharmacokinetics: Advantages for drug therapy?**

Co-chairs
- M. Tsuchiya, Gotenba, Japan
- B. Leufkens, Utrecht, The Netherlands
- H. Kroemer, Greifswald, Germany
- W. Evans, Memphis, TN USA

*14:15*
- When are dose administration aids of benefit?
  - M. Roberts, Brisbane, Australia

*14:50*
- The challenge of the next generation of therapeutic antibodies
  - M. Tsuchiya, Gotenba, Japan

*15:25*
- Medication errors and human factors in medication use safety
  - P. Schneider, Columbus, OH USA

*16:00*
- Short Podium Presentation
  - Short Podium Presentation

*16:15*
- Short Podium Presentation
  - Short Podium Presentation

**EUFEPS Afternoon Session**

*16:45*
- See framed information, page 11
## Parallel Symposium
**Systems Biology: A driver of drug discovery and development?**
- **Co-chairs**
  - C.R. Noe, Vienna, Austria

**08:30**
- Theory of biological robustness and system drug design
  - H. Kitano, Tokyo, Japan

**09:05**
- Systems Biology: What does it mean for pharmaceutical sciences?
  - A. Aszódi and C.R. Noe, Vienna, Austria

**09:40**
- **Coffee Break**

**10:45**
- Short Podium Presentation

**11:15**
- **Posters**
- **Lunch Break**

## Parallel Symposium
**How to engineer desired particle properties for drug delivery?**
- **Co-chairs**
  - E. Fattal, Paris, France
  - T. Nagat, Tokyo, Japan

**09:05**
- Particle design for nucleic acids and contrast agents
  - E. Fattal, Paris, France

**10:45**
- Novel particle design for drug delivery
  - H. Takeuchi, Gifu, Japan

**11:15**
- **Short Podium Presentation**

## Parallel Symposium
**Off-label use of medicines: Abuse or a vehicle for innovation?**
- **Co-chairs**

**08:30**
- Two worlds and why the twain will never meet
  - J. Lisman, The Hague, The Netherlands

**10:45**
- Regulatory and economic aspects of the off-label use of medicines
  - A. Wertheimer, Philadelphia, PA USA

**14:15**
- **Suramin: A systems modulator of multiple molecular targets**
  - J. Au, Columbus, OH USA

**14:50**
- **A systems pharmacology: Targeting p53 networks**
  - E. Liu, Singapore, Singapore

**15:25**
- **The challenges of developing targeted cancer therapies: An industry perspective**
  - S. Eck, Ann Arbor, MI USA

**16:45**
- **Counterfeiting of medicines: Detection and prevention?**
  - Co-chairs
    - A. Moffat, London, United Kingdom
    - Z. Y. Yang, Guangzhou, China

**14:15**
- **Separation based sensors for pharmaceutical analysis using microdialysis and microchip electrophoresis**
  - S. Lunte, Lawrence, KS USA

**14:50**
- **Micro and nano chemical systems on chips for analytical and biological sciences**
  - T. Kitamori, Tokyo, Japan

**15:25**
- **Microchip strategies for biomarker detection and screening utilizing fluorescence and MALDI-TOF MS readout**
  - T. Laurell, Lund, Sweden

**16:00**
- **Combating counterfeiting in Asia**
  - Z. Y. Yang, Guangzhou, China

**16:15**
- **Combating counterfeiting initiative**
  - F. Fricke, Cincinnati, USA